A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Emixustat (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms SEATTLE
  • Sponsors Acucela
  • Most Recent Events

    • 13 Jun 2016 According to an Acucela Inc. media release, the company will discontinue further analysis of the clinical data from this study pertaining to geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
    • 31 May 2016 Status changed from active, no longer recruiting to completed.
    • 25 May 2016 Top-line results published in the Acucela media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top